ACE2 and COVID-19: The assay was developed to investigate if and to what extent COVID-19 convalescent subjects mount antibody responses capable of blocking the RBD–ACE2 interaction and thus was initially thought to serve as surrogate test to estimate protection against future SARS-CoV-2 infections.